CurrentAvMedPolicy N/A

Orencia (abatacept) for GVHD prophylaxis

Defines prior authorization and clinical criteria for IV abatacept (J0129) when used for prophylaxis of acute graft-versus-host disease in hematopoietic stem cell transplant recipients; applies to AvMed members and prescribing providers requesting medical benefit authorization.

Policy Summary

PayerAvMed

PolicyOrencia (abatacept) for GVHD prophylaxis

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionSubmit a completed medical prior authorization form with prescriber signature and required clinical documentation and fax to AvMed.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

4Quantity limit (recommended dosing course)

10 mg/kgDose per administration

>=2Minimum age (years)

Matched or 1-alleleAllowed donor types

6 moEBV prophylaxis duration

Coverage Criteria for IV Abatacept (Orencia)

Initial Authorization Criteria

Covered when ALL of the following are met

Age: Member is 2 years of age or older>=2 years

Transplant type: Member is undergoing a hematopoietic stem cell transplant (HSCT) from a matched or 1 allele-mismatched unrelated-donormatched or 1-allele mismatched unrelated donor

Indication: Medication will be used for prophylaxis of acute graft versus host disease (aGVHD) (IV formulation only)IV formulation only

Policy Summary

PayerAvMed

PolicyOrencia (abatacept) for GVHD prophylaxis

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionSubmit a completed medical prior authorization form with prescriber signature and required clinical documentation and fax to AvMed.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Authorization, Documentation, and Submission Requirements

Prior Authorization

Prior Authorization Required

Prior authorization required for IV abatacept (J0129) when requested for graft-versus-host disease (GVHD) prophylaxis. Complete the medical prior authorization form and provide all requested clinical information to avoid delays.

Affected code: J0129 (IV abatacept)
Indication: Prophylaxis of acute GVHD (IV infusion only)
Quantity limit: 4 vials (total of 4 doses)

Step Therapy

Samples and Prior Therapy Verification

Use of medication samples to initiate therapy does not meet step edit/preauthorization criteria. Prior therapies will be verified via pharmacy paid claims and/or submitted chart notes; include documentation of prior therapies when applicable.

Samples do not satisfy preauthorization or step-therapy requirements
Previous therapies will be verified through pharmacy paid claims or submitted chart notes

Documentation Required

Required Signatures and Supporting Documentation

Prescriber signature is required on the prior authorization request (preprinted stamps are not valid). To support each checked clinical criterion, provide documentation including lab results, diagnostics, and chart notes; incomplete supporting documentation may result in denial.

Prescribing physician must sign and clearly print name on the request
Provide supporting documentation for each checked clinical criterion (labs, diagnostics, chart notes)
For Medicare members, comply with applicable NCDs/LCDs and reference CMS Medicare Coverage Database

Denial Risk

Incomplete Documentation Risks Denial

Authorization can be delayed or denied if information provided is incomplete, incorrect, or illegible. Ensure all sections of the form are completed (drug form/strength, dosing schedule, length of therapy, diagnosis, ICD code if applicable, weight, date, and appropriate review timeframe selection).

Complete drug information: form/strength, dosing schedule, length of therapy, diagnosis, ICD code (if applicable), weight, date
Select Standard or Urgent review appropriately; for urgent reviews contact AvMed Pre-Authorization Department
If medication is provided by a specialty pharmacy, indicate (PropriumRx) or provide location/site NPI/DEA for administering location

Background

Abatacept (Orencia) is provided as an intravenous formulation for use as prophylaxis against acute graft-versus-host disease in patients undergoing hematopoietic stem cell transplant (HSCT). The policy requires that members be ≥ 2 years of age, receiving HSCT from a matched or 1-allele mismatched unrelated donor, and that abatacept be given only as the IV formulation in combination with a calcineurin inhibitor (e.g., cyclosporine or tacrolimus) and methotrexate. The member must also receive antiviral prophylaxis for Epstein-Barr Virus (EBV) with prophylaxis continued for 6 months post-transplant and be monitored for EBV reactivation and cytomegalovirus (CMV) infection/reactivation. Documentation such as lab results, diagnostics, and chart notes must be provided to support each criterion.

Definitions and Clinical Context

Prophylaxis of acute graft-versus-host disease (aGVHD)

IndicationProphylaxis of acute graft-versus-host disease (aGVHD) in HSCT recipients

Required combination therapyUse in combination with a calcineurin inhibitor (e.g., cyclosporine or tacrolimus) and methotrexate

Formulation restrictionIV formulation only

Age eligibilityMember is 2 years of age or older

Donor typeHSCT from a matched or 1‑allele mismatched unrelated donor

Most actionable requirementUse IV abatacept with a calcineurin inhibitor + methotrexate to prevent development of aGVHD (must meet all listed criteria for approval)

OpenPayer

Orencia (abatacept) for GVHD prophylaxis

Coverage Criteria for IV Abatacept (Orencia)

Billing and Dosing Information

Authorization, Documentation, and Submission Requirements

Background

Definitions and Clinical Context